RxDoctor Payments Data

Nicolette Orsky

Physician Assistant · Greenville, SCNPI 1538724992

Payments from drug & device makers

$3,202in general payments, 2019–2025

Across 171 payments — averaging $18.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Johnson & Johnson$561
  • Sanofi$291
  • Takeda Pharmaceuticals U.S.A., Inc.$273
  • Pfizer$109
  • Lilly USA, LLC$97
  • plus $787 from 16 others

What the payments were for

  • Food & beverage$3,11397%
  • Education$893%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,202 in reported general payments places this provider in the 80th percentile of 1,852 physician assistant providers in South Carolina.

See all physician assistant providers in South Carolina

Medicare billing

Part B allowed, 2024
$17,005
Medicare patients
126
Services billed
209

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab26$692,458
Skyrizi On-BodyRisankizumab-Rzaa15$282,237
RinvoqUpadacitinib31$273,374
XifaxanRifaximin48$142,036
Dupixent PenDupilumab14$109,241
LinzessLinaclotide27$27,289
MotegrityPrucalopride Succinate12$12,379
Dexlansoprazole DrDexlansoprazole23$9,549
Balsalazide Disodium16$3,287
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates33$2,711
Famotidine160$1,893
Omeprazole126$1,427
Sucralfate23$1,402
Colestipol Hcl13$1,378
Pantoprazole Sodium102$1,328

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$561$692,45826 claims
AbbVieRinvoq, Linzess$1,084$300,66358 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$72$142,03648 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$273$12,37912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,852 physician assistant providers in South Carolina.

Other physician assistant in Greenville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →